{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:57:37Z","timestamp":1780624657292,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40263-023-01024-5","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T14:02:50Z","timestamp":1689775370000},"page":"725-731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Acute Valproate-Induced Encephalopathy in Status Epilepticus: A Registry-Based Assessment"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2609-6843","authenticated-orcid":false,"given":"Valentin","family":"Loser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-7083","authenticated-orcid":false,"given":"Jan","family":"Novy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9300-4443","authenticated-orcid":false,"given":"Isabelle","family":"Beuchat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7878-172X","authenticated-orcid":false,"given":"Andrea O.","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"1024_CR1","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/epi.13121","volume":"56","author":"E Trinka","year":"2015","unstructured":"Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus-report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56:1515\u201323.","journal-title":"Epilepsia"},{"key":"1024_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1468-1331.2009.02917.x","volume":"17","author":"H Meierkord","year":"2010","unstructured":"Meierkord H, Boon P, Engelsen B, et al. European Federation of Neurological Societies. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17:348\u201355.","journal-title":"Eur J Neurol."},{"key":"1024_CR3","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","volume":"381","author":"J Kapur","year":"2019","unstructured":"Kapur J, Elm J, Chamberlain JM, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381:2103\u201313.","journal-title":"N Engl J Med."},{"key":"1024_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40263-017-0424-1","volume":"31","author":"I Beuchat","year":"2017","unstructured":"Beuchat I, Novy J, Rossetti AO. Newer antiepileptic drugs in status epilepticus: prescription trends and outcomes in comparison with traditional agents. CNS Drugs. 2017;31:327\u201334.","journal-title":"CNS Drugs"},{"key":"1024_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1528-1167.2012.03532.x","volume":"54","author":"Y Noh","year":"2013","unstructured":"Noh Y, Kim DW, Chu K, et al. Topiramate increases the risk of valproic acid-induced encephalopathy. Epilepsia. 2013;54:1\u20134.","journal-title":"Epilepsia"},{"key":"1024_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.psym.2017.02.003","volume":"58","author":"C Lewis","year":"2017","unstructured":"Lewis C, Tesar GE, Dale R. Valproate-induced hyperammonemic encephalopathy in general hospital patients with one or more psychiatric disorders. Psychosomatics. 2017;58:415\u201320.","journal-title":"Psychosomatics"},{"key":"1024_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5214\/ans.0972.7531.210210","volume":"21","author":"O Farooq","year":"2014","unstructured":"Farooq O, Zunga PM, Dar MI, et al. Non-Hyperammonemic valproate encephalopathy. Ann Neurosci. 2014;21:76\u20139.","journal-title":"Ann Neurosci."},{"key":"1024_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107967","volume":"120","author":"J Wu","year":"2021","unstructured":"Wu J, Li J, Jing W, et al. Valproic acid-induced encephalopathy: a review of clinical features, risk factors, diagnosis, and treatment. Epilepsy Behav. 2021;120: 107967.","journal-title":"Epilepsy Behav"},{"key":"1024_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00655.x","volume":"114","author":"N Segura-Bruna","year":"2006","unstructured":"Segura-Bruna N, Rodriguez-Campello A, Puente V, et al. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand. 2006;114:1\u20137.","journal-title":"Acta Neurol Scand"},{"key":"1024_CR10","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1111\/j.1468-1331.2006.01394.x","volume":"13","author":"N Embacher","year":"2006","unstructured":"Embacher N, Karner E, Wanschitz J, et al. Acute encephalopathy after intravenous administration of valproate in non-convulsive status epilepticus. Eur J Neurol. 2006;13:e5-6.","journal-title":"Eur J Neurol"},{"key":"1024_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/NRL.0000000000000335","volume":"26","author":"KM Smith","year":"2021","unstructured":"Smith KM, Britton JW, Hocker SE, et al. Hyperammonemia in patients with status epilepticus treated with or without valproic acid. Neurologist. 2021;26:80\u20132.","journal-title":"Neurologist"},{"key":"1024_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.seizure.2019.03.020","volume":"69","author":"J Lind","year":"2019","unstructured":"Lind J, Nordlund P. Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia. Seizure. 2019;69:20\u20134.","journal-title":"Seizure."},{"key":"1024_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107193","volume":"111","author":"SF Habhab","year":"2020","unstructured":"Habhab SF, Ulvin LB, Taub\u00f8ll E, et al. Influence of valproate-induced hyperammonemia on treatment decision in an adult status epilepticus cohort. Epilepsy Behav. 2020;111: 107193.","journal-title":"Epilepsy Behav"},{"key":"1024_CR14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S1474-4422(16)30137-5","volume":"15","author":"M Leitinger","year":"2016","unstructured":"Leitinger M, Trinka E, Gardella E, et al. Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study. Lancet Neurol. 2016;15:1054\u201362.","journal-title":"Lancet Neurol"},{"key":"1024_CR15","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1111\/ene.15441","volume":"29","author":"S Vijiala","year":"2022","unstructured":"Vijiala S, Andr\u00e9 P, Buclin T, et al. Valproate in status epilepticus: correlation between loading dose, serum levels, and clinical response. Eur J Neurol. 2022;29:2607\u201311.","journal-title":"Eur J Neurol"},{"key":"1024_CR16","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00415-008-0989-1","volume":"255","author":"AO Rossetti","year":"2008","unstructured":"Rossetti AO, Logroscino G, Milligan TA, et al. Status epilepticus severity score (STESS): a tool to orient early treatment strategy. J Neurol. 2008;255:1561\u20136.","journal-title":"J Neurol"},{"issue":"6","key":"1024_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s40263-023-01013-8","volume":"37","author":"LM Willems","year":"2023","unstructured":"Willems LM, van der Goten M, von Podewils F, et al. Adverse event profiles of antiseizure medications and the impact of coadministration on drug tolerability in adults with epilepsy. CNS Drugs. 2023;37(6):531\u201344.","journal-title":"CNS Drugs"},{"issue":"12","key":"1024_CR18","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1111\/epi.16382","volume":"60","author":"A Fechner","year":"2019","unstructured":"Fechner A, Hubert K, Jahnke K, et al. Treatment of refractory and superrefractory status epilepticus with topiramate: a cohort study of 106 patients and a review of the literature. Epilepsia. 2019;60(12):2448\u201358.","journal-title":"Epilepsia"},{"key":"1024_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.seizure.2016.09.015","volume":"43","author":"K Sato","year":"2016","unstructured":"Sato K, Arai N, Omori A, et al. Hyperammonaemia and associated factors in unprovoked convulsive seizures: a cross-sectional study. Seizure. 2016;43:6\u201312.","journal-title":"Seizure."},{"key":"1024_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/epi.14607","volume":"60","author":"M Leitinger","year":"2019","unstructured":"Leitinger M, Trinka E, Giovannini G, et al. Epidemiology of status epilepticus in adults: a population-based study on incidence, causes, and outcomes. Epilepsia. 2019;60:53\u201362.","journal-title":"Epilepsia"},{"issue":"1","key":"1024_CR21","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1212\/WNL.0000000000011000","volume":"96","author":"U Fisch","year":"2021","unstructured":"Fisch U, Baumann SM, Semmlack S, et al. Accuracy of calculated free valproate levels in adult patients with status epilepticus. Neurology. 2021;96(1):e102\u201310.","journal-title":"Neurology"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01024-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01024-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01024-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T12:28:41Z","timestamp":1692361721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01024-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01024-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"27 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open\naccess funding provided by University of Lausanne. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None of the authors has any conflict of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Given that anonymized data were used, there was no need for ethics commission approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As this is primarily a quality study of treatment practice, and given that anonymized data were used, the Swiss Human Research Act does not require patient consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that supports the findings of this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"VL: methodology (supporting), formal analysis, investigations (equal), writing\u2014original draft preparation (leading). JN: writing\u2014review and editing (equal). IB: writing\u2014review and editing (equal). AOR: conceptualization, methodology (leading), investigations (equal), resources, supervision, writing\u2014original draft preparation (supporting), writing\u2014review and editing (equal). All authors wrote, edited, and significantly contributed to the final manuscript. All authors approved the final manuscript for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}